To examine if VHL-null ccRCC can be re-sensitized to sorafenib treatment in vivo, we subcutaneously transplanted VHL-null 786-O cells into immunocompromised SCID mice. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.